Questions List

Hi allPosted onApril 2, 2021 8:25 am

Posted onApril 2, 2021 8:21 am

Posted onApril 2, 2021 8:21 am

Posted onApril 2, 2021 8:21 am

Posted onApril 2, 2021 8:21 am

Posted onApril 2, 2021 8:21 am

Posted onApril 2, 2021 8:21 am

Posted onApril 2, 2021 8:12 am

Posted onApril 2, 2021 8:09 am

Posted onApril 2, 2021 8:09 am

Posted onApril 2, 2021 8:03 am

Posted onApril 2, 2021 8:01 am

All thanks for all participatantPosted onApril 2, 2021 7:52 am

Hello, thanks for the update.Posted onApril 2, 2021 5:12 am

Posted onApril 2, 2021 3:52 am

NoPosted onApril 2, 2021 1:13 am

NoPosted onApril 2, 2021 12:59 am

TestPosted onApril 1, 2021 10:54 am

hiPosted onApril 1, 2021 10:12 am

hello Posted onApril 1, 2021 9:58 am

Hello i have a question Posted onSeptember 2, 2020 11:19 am

How would you treat biphenotipic T-ALL/AML?Posted onJuly 2, 2020 3:37 pm

To what degree does the anti CD38 antibody affect the normal T-cell populations?Posted onJuly 2, 2020 3:28 pm

Could the use of NTI7 negatively affect CAR T cell longevity or exhaustion? Posted onJuly 2, 2020 3:27 pm

Treatment of T all in 60y old patient?Posted onJuly 2, 2020 3:01 pm

***** 20 Debate *************Posted onJuly 2, 2020 2:47 pm

option 2Posted onJuly 2, 2020 2:47 pm

Do you have any explanation why anti TIM 3 should work better in high risk MDS?Posted onJuly 2, 2020 2:22 pm

Posted onJuly 2, 2020 2:22 pm

i have 67 years old male with flt3 negative aml who relapsed after allSCT he didnt go into CR after 1 cycle aza and venetoclax what is your suggestion pleasePosted onJuly 2, 2020 2:22 pm

How would one treat BM and CNS relapse in patients who have not previously tolerated high dose methotrexate? Can inotuzumab treat CNS disease? Posted onJuly 2, 2020 2:00 pm

Would it be reasonable to use ARAC for debulking, in order to preserve more the T cell compartment?Posted onJuly 2, 2020 1:56 pm

How can we choose the optimal treatment between CAR-T and BITe?Posted onJuly 2, 2020 1:12 pm

Dr Rijneveld, when is the best moment after debulking with cyclophosphamide for use Blina? I mean, after two weeks? Immediatly after the infusion of cyclophosphamide? And what the dose for debulking with cyclophosphamide for use Blina?Posted onJuly 2, 2020 1:07 pm

50% MRD (-) after Blina, and what about other 50% of patients What have we to do with them?Posted onJuly 2, 2020 1:02 pm

why did you give Blina after second relapse after allo-sct and not InO in the first case?Posted onJuly 2, 2020 12:56 pm

In the case of high WBC why not hyperCVAD?Posted onJuly 2, 2020 12:53 pm

Why favours IO if MUD donor?Posted onJuly 2, 2020 12:51 pm

The patient was CD20+. Why didn't you use rituximab at the begining of the treatment?Posted onJuly 2, 2020 12:50 pm

************** Session 19 **************Posted onJuly 2, 2020 12:28 pm

Are there any updates for the management of leukemia in FA patients?Posted onJuly 2, 2020 10:16 am

In a patient with IDH1/2 persistence after chemotherapy, if no clinical trial is available, would you consider aza, possibly as a bridge to transplant?Posted onJuly 2, 2020 10:13 am

Posted onJuly 2, 2020 9:47 am

Are you able to see my question?Posted onJuly 2, 2020 9:17 am

********* Day 3 *************Posted onJuly 2, 2020 6:55 am

When you talk about HMAs, do you restrict that to people with blasts < 30% only?Posted onJuly 1, 2020 4:26 pm

What percentage of patients show CEBPA mutations? Do you test for CEBPA mutations only by Next Generation Sequencing?Posted onJuly 1, 2020 4:19 pm

What is the average number of cycles do you give with low dose cytarabine in unfit elderly AML patients?Posted onJuly 1, 2020 4:10 pm

Can we expect MRD to be used for AML in clinical routine?Posted onJuly 1, 2020 4:09 pm

What specific Geriatric assesment tool would you recommend to use to define a AML patient as fit or unfit? wHAT DO YOU DO IN YOUR HOSPITAL'Posted onJuly 1, 2020 4:06 pm

Question for Lars please: What percentage of patients have multiple FLT3 ITD clones? Are you observing increased risk of relapse or shorter durations of response to flt3 inhibition in patients with multiple clones? Posted onJuly 1, 2020 4:06 pm

How could you explain the absence of OS improvement in some LI thepay study?Posted onJuly 1, 2020 4:06 pm

Have you got any idea about using WT1 like a universal MRD marker&Posted onJuly 1, 2020 3:46 pm

************* Novartis **************Posted onJuly 1, 2020 3:30 pm

Would you consider VEN + LDAC in the patient with FLT3mut AML that fails an HMA for a previous high-risk MDS? WOuld you add a FLT3 inhibitor?Posted onJuly 1, 2020 3:02 pm

Would you consider VEN + LDAC in the patient with FLT3mut AML that fails an HMA for a previous high-risk MDS? WOuld you add a FLT3 inhibitor?Posted onJuly 1, 2020 3:02 pm

great talks thanks..what are your recommendations for resource poor countries like Pakistan where i work,lots of acute myeloid leukemics are young,cant afford transplant,what are your recommemndations for these young high risk patients who cant get allo SCT, any guidance regarding consolidationPosted onJuly 1, 2020 2:57 pm

To avoid VOD, is it better to wait some time between GO and HSCT, just like it is suggested for inotuzumab?Posted onJuly 1, 2020 2:52 pm

To Nigel Russell - do you still think an MRD peripheral blood approach post course 2 to guide transplant is valid for triple mutations (DNMT3A/Flt3/NPM1) and Flt3 high allelic ratio/NPM1 patients.Posted onJuly 1, 2020 2:47 pm

The consolidation in ALFA 0701 study did not contain HDAC and we know that HDAC is an important drug for the consolidation especially in favorable risk patient who did not undergo HSCT. Did you recommend to proceed to consolidation with HDAC + GO or consolidation as in the study?Posted onJuly 1, 2020 2:38 pm

For Dr- Russell: Why not combining FLAG-Ida and Venetoclax?Posted onJuly 1, 2020 2:29 pm

According to your data and case report maybe we have to use FLAG-Ida like induction therapy for all de novo AML patients?Posted onJuly 1, 2020 2:28 pm

wHAT IS THE ROLE OF NPM MONITORING IN flt3 +ve ,npm mutated AML Can we avoid transplant, if patient is monitored for NPm and midostaurin?Posted onJuly 1, 2020 2:25 pm

to Dr Lambert: are there any data supporting the use of GO in association with midostaurin in FLT3-ITD AML patients?Posted onJuly 1, 2020 2:11 pm

How could you discriminate the effectiveness of ATRA and GO in your trial?Posted onJuly 1, 2020 2:08 pm

Is there a b.line to discriminate high and low CD33 expression&Posted onJuly 1, 2020 2:05 pm

According to meta-analysis whether it is rationale tu use GO in AML patients with High risk prognosis?Posted onJuly 1, 2020 1:59 pm

To Dr Sierra: do you think maintenance with midostaurine after HSCT is better than sorafenib in FLT3-ITD AML? Posted onJuly 1, 2020 1:50 pm

Is it possible to use FLT3 inhibitors after AlloSCT in AML patients MRD (+) and MRD (-) or we have to do it differently according to MRD status?Posted onJuly 1, 2020 1:47 pm

********* Session 16 **************Posted onJuly 1, 2020 1:34 pm

To Dr Cortes: can you comment on cardiac toxicities with CPX-351? It is sometimes said that cardiac tolerance is better with this formulation, and that it could be used in patients with impaired <50% left ventricular function, do you think this is true?Posted onJuly 1, 2020 1:06 pm

How would you treat a patient with FLT3-ITDmut AML who progresses after several cycles of azacitidine for EB-MDS?Posted onJuly 1, 2020 1:04 pm

In an unfit AML patient starting with severe neutropenia, would you consider reducing venetoclax to 100-200 mg? Posted onJuly 1, 2020 12:57 pm

How do you perform fungal prophylaxis in outpatients treated with venetoclax and aza/decitabinePosted onJuly 1, 2020 12:56 pm

If we use these new drugs, even triple combinations, with unlimited number of cycles, when do we have to look at pharmacoeconomics.Posted onJuly 1, 2020 12:55 pm

Thank you for the Presentation Dr Wei - currently what would be you perffered/optimal treatment of de novo FLT3+NMP1+ AML elderly patient?Posted onJuly 1, 2020 12:55 pm

Considering the low toxicity of cpx351, when would you consider cpx351 and when venetoclax-aza in a 65-70 year-old secondary AML patient?Posted onJuly 1, 2020 12:54 pm

Posted onJuly 1, 2020 12:48 pm

can you comment on efficacy of venetoclax+HMA in refractory AML?Posted onJuly 1, 2020 12:44 pm

How to treat AML with TP53 disruption? both fit/young and unfit/older? ThanksPosted onJuly 1, 2020 12:06 pm

******* Session 15 ***************Posted onJuly 1, 2020 12:01 pm

How do we stratify NPM1 and FLT3-TKD co-mutated patients? Posted onJuly 1, 2020 11:23 am

What methods are used for molecular screening for results in 24-48 hours (since screening and NGS was mentioned spearately)?Posted onJuly 1, 2020 11:17 am

Will you consider the same high risk value for FLT3 TKD and FLT3 ITD? Posted onJuly 1, 2020 11:06 am

Posted onJuly 1, 2020 10:49 am

********* BMS ***********Posted onJuly 1, 2020 10:17 am

Option 1Posted onJuly 1, 2020 10:15 am

In case of 65 year old man patient with NPM1 mutant AML, would you treat with intensive chemotherapy or hypomethylating agents and venetoclax? Posted onJuly 1, 2020 10:12 am

Excellent debate! ArnoldPosted onJuly 1, 2020 10:12 am

Option 1Posted onJuly 1, 2020 10:09 am

The second optionPosted onJuly 1, 2020 10:08 am

Option1Posted onJuly 1, 2020 10:07 am

Thanks for your great presentations!I basically agree with both the speakers. In the patients with persistent molecular NPm1 positivity after one or two consolidations, are they considered at high risk? For those patients, who can be considered chemo-resistant, which is the best option: intensive or targeted therapy, in particular for older patient? R. Cerretti from Rome, ItalyPosted onJuly 1, 2020 10:03 am

A question for Dr. Ali: A NPM1mut AML patient, unfit for AlloSCT, has positive MRD at the end of consolidation. Would you reccommend azacitidine maintenance, or another option?Posted onJuly 1, 2020 10:00 am

A question for Dr. Rollig: In young fit NPM1mutated AML, which dose of consolidation HiDAC would you reccommend - 1500 mg/m2 or 3000 mg/m2? Thank you!Posted onJuly 1, 2020 9:58 am

If it is a result of intensive CH how many courses of HD Ara-C consolidation is optimal?Posted onJuly 1, 2020 9:49 am

Is it a routine practice to determine as much mutations as it is possible to determine correct prognosis of AML NMPM1 mut (+) patients?Posted onJuly 1, 2020 9:47 am

Thank you for the presentation- in your opinion what is the optimal treatment of FLT3+ NPM1 mutated patient in CR (MRD -) post intensive chemo consolidation (ie. 7+3 + midostaurin)?Posted onJuly 1, 2020 9:45 am

To Dr. Röllig: Negative effect of Flt3-ITD depends on allelic ratio. Is that also true for other negative co-mutations?Posted onJuly 1, 2020 9:39 am

**** Debate *****Posted onJuly 1, 2020 9:30 am

Do you give prophylactic intrathecal chemotherapy in APL relapse, even if the patient had low-risk APL at diagnosis?Posted onJuly 1, 2020 9:25 am

You indicate the APOLLO trial will establish the best treatment, but it is only comparing two options. Other options exist, such as the NCRI AML17 protocol, and the ALLG APML4 protocol. Posted onJuly 1, 2020 9:15 am

DPosted onJuly 1, 2020 9:09 am

How do I vote?Posted onJuly 1, 2020 9:09 am

Posted onJuly 1, 2020 9:00 am

would you consider sequential conditioning in these patients with MRD+?Posted onJuly 1, 2020 8:47 am

To Dr Craddock and Dr Sierra: do you use 5-aza as relapse prevention in high risk AML patients outside of clinical trials?Posted onJuly 1, 2020 8:43 am

MRD is a time-point dependent variable. MRD negativity is not synonymous with the absence of residual disease and current treatment protocols require a sensitivity of at least 0.0001 rather than 0.1 in the study presented here. Please comment.Posted onJuly 1, 2020 8:43 am

The balance between GVT and GVHD is influenced by the genetic disparity between donor and recipient, origin of antigen presenting cells provoking immune response, etc. Are these factors taken to consideration while considering risk of GVHD?Posted onJuly 1, 2020 8:34 am

To Dr Giralt: do you routinely use prophylaxis with defibrotide in high risk adult patients undergoing allo-HSCT in your clinic? Posted onJuly 1, 2020 8:28 am

*********** Day 2 ****************Posted onJuly 1, 2020 6:20 am

Try1Posted onJuly 1, 2020 12:08 am

Hello again it's mePosted onJuly 1, 2020 12:02 am

Test 123Posted onJuly 1, 2020 12:01 am

Did you check the patients whether they have leukemia pre-disposition disorders / iBMFs like Shwachman-Diamond Syndrome (due to SBDS mutations)?Posted onJune 30, 2020 4:48 pm

IDH inhibitors role post HSCT?Posted onJune 30, 2020 4:26 pm

in patient 70 y.old Secondary AML with DNMT3 + IDh2 at diagnosis. Achieve CR with Venetoclax + Aza and after 1 1/2 year relapse did you considere to use some other drug Posted onJune 30, 2020 4:25 pm

Could use of targeted therapies during induction lead to selection of resistance and therefore reduce the benefit of these therapies post transplant for minimal residual disease/maintenance?Posted onJune 30, 2020 4:24 pm

Posted onJune 30, 2020 4:13 pm

Was the response to sorafenib augmented by donor lymphocyte infusions?Posted onJune 30, 2020 3:37 pm

Session 9 break point Posted onJune 30, 2020 3:34 pm

BPosted onJune 30, 2020 3:29 pm

What do you think about using midostaurin for CBF-AML patients with kit mutations? Posted onJune 30, 2020 3:25 pm

What do you think about using midostaurin for CBF-AML patients with kit mutations? Posted onJune 30, 2020 3:25 pm

What do you think about using midostaurin for CBF-AML patients with kit mutations? Posted onJune 30, 2020 3:25 pm

3Posted onJune 30, 2020 3:17 pm

To Dr Sarah Tasian: What data is there on prognosis of CRLF2 rearranged Down's ALL patients? Posted onJune 30, 2020 3:16 pm

BPosted onJune 30, 2020 3:11 pm

Excellent session. Very helpful for clearing alot of dilemmas we face in such rare cases. Thank youPosted onJune 30, 2020 2:52 pm

Dear dr. Lucy Godley, do You check DDX1 gene in bone marrow samples? Or skin biopsy samples? In addition, what additional measures are taken if germline mutation is found? Do You consult and test family members or do You refer to geneticist? Posted onJune 30, 2020 2:31 pm

Dr Godley - excellent presentation. Would you recommend that all GATA 2 variants need to be characterized as somatic or germline even including variants of uncertain significance ?Posted onJune 30, 2020 2:31 pm

To Dr Godley: there are tumour mutation signatures for HR deficiency associated with BRCA loss. Have these been demonstrated in haematological cancers to show that the germline BRCA mutations are contributing to the development of haematological cancers, for example in your case with the BRCA1 deletion and DLBCL/AML? Posted onJune 30, 2020 2:15 pm

Congratulations to all of you. Arnold GanserPosted onJune 30, 2020 1:09 pm

If physician is in doubt about Transplant and the patient is inclined towards transplant or no transplant, is that makes any difference in the decision.Posted onJune 30, 2020 1:02 pm

NoPosted onJune 30, 2020 1:01 pm

Will we ever be able to answer these questions from clinical trials? Shouldn´t we enter all our data (clinical, genetic, molecular genetic, etc.) into a big data registry comparable to the one by Gerstug et al, Nat Genetics, to come up with scores and predicions of outcome with/without SCT in CR1?Posted onJune 30, 2020 1:01 pm

At the begining Ms.Roboz said that she was given the "No" part of the debate by organizers. What is her actual opinion? Is she for or against? Thank you.Posted onJune 30, 2020 12:58 pm

Is there a role for greater use of PT-Cy for older patients with unrelated donors? Posted onJune 30, 2020 12:56 pm

yes Posted onJune 30, 2020 12:51 pm

yes Posted onJune 30, 2020 12:51 pm

noPosted onJune 30, 2020 12:50 pm

Regarding the suggested 40% plateau in the Aza/Venetoclax study: how many patients in the Aza/Ven arm went on to transplantation? Posted onJune 30, 2020 12:49 pm

Regarding the suggested 40% plateau in the Aza/Venetoclax study: how many patients in the Aza/Ven arm went on to transplantation? Posted onJune 30, 2020 12:49 pm

NoPosted onJune 30, 2020 12:22 pm

yes Posted onJune 30, 2020 12:21 pm

noPosted onJune 30, 2020 12:21 pm

With the data available today, would you transplant a patient in CR1 which became MRD negative after blinatumomab?Would you consider the "amount" of MRD pre blinatumomab?Posted onJune 30, 2020 12:05 pm

With the data available today, would you transplant a patient in CR1 which became MRD negative after blinatumomab?Would you consider the "amount" of MRD pre blinatumomab?Posted onJune 30, 2020 12:05 pm

in the expanded access cohort, did you see any difference in OS between transplanted patients and those who did not have transplant? regards Sahra Ali Guys and St Thomas Hospitals. LondonPosted onJune 30, 2020 11:52 am

in the expanded access cohort, did you see any difference in OS between transplanted patients and those who did not have transplant? regards Sahra Ali Guys and St Thomas Hospitals. LondonPosted onJune 30, 2020 11:52 am

i have 28 years lady with Burkitt lymphoma stage 4 who responded well to HyperCVAD but shortly developed local progrseeion * right iiliac fossa(while on chemotherapy , what is your suggestion for next step in therapyPosted onJune 30, 2020 11:51 am

i have 28 years lady with Burkitt lymphoma stage 4 who responded well to HyperCVAD but shortly developed local progrseeion * right iiliac fossa(while on chemotherapy , what is your suggestion for next step in therapyPosted onJune 30, 2020 11:51 am

Posted onJune 30, 2020 11:48 am

could you comment on the conditioning regimen before all HSCT in the blast-stay?Posted onJune 30, 2020 11:46 am

.Posted onJune 30, 2020 11:38 am

Posted onJune 30, 2020 11:31 am

What is the mechanism for the prolonged cytopenias (in those without HLH/MAS)?Posted onJune 30, 2020 11:30 am

Please share your experience on the mutation in the primary leukemic cells leading to ineffective CART cell therapy during remission or relapse?Posted onJune 30, 2020 11:27 am

Posted onJune 30, 2020 11:22 am

Break for Amgen SympoPosted onJune 30, 2020 10:40 am

would you transplant a patient with bcr/abl positive, IG rearrangements negative asset? Posted onJune 30, 2020 10:13 am

Have you looked at TET2, DNMT3A and other CHIP associated mutations in the elderly bcr-abl positive ALL patients?Posted onJune 30, 2020 10:13 am

To Dre Clappier: 1. do you know if this phenomenon can occur in healthy patients (like a CHIP?) 2. Do you recommend IgHTCR MRD follow up in routine in Ph+ ALL patients?Posted onJune 30, 2020 9:53 am

Question to Dr Murphy: Have tried to investigate the presence of LSC signature in MRD or Relpase?Posted onJune 30, 2020 9:36 am

Question Dr Cloos: Does the assessment of LSCs frequency by FACS should be performed on both PB and BM samples or PB is enough?Posted onJune 30, 2020 9:35 am

To Dr Cloos: can you clarify a little bit more depth how, in a patient with AML during follow up, you are able to differentiate the LSCs from the residual blasts? CD34-CD38- cells with aberrant markers could be AML blasts and not LSCs, couldn't they?Posted onJune 30, 2020 9:34 am

Session 4: Tracking leukaemic stem cells Posted onJune 30, 2020 9:01 am

Posted onJune 30, 2020 8:36 am

Question to all: Are the markers time dependent as to prognosis?Posted onJune 30, 2020 8:27 am

Georgina- Have you checked the utility of nano-string technique in B-ALL?Posted onJune 30, 2020 8:27 am

Congratulations to you all for the excellent presentations and the discussion. ArnoldPosted onJune 30, 2020 8:23 am

Hello can you clarify what "unbiased approach" means in this context?Posted onJune 30, 2020 8:21 am

Question to Dr. Bullinger: How important is VAF?Posted onJune 30, 2020 8:10 am

To Georgina: Do you have preliminary results on the cost-effectiveness of your global approach? I mean at the consolidated cost level. Hervé Dombret, ParisPosted onJune 30, 2020 8:09 am

Posted onJune 30, 2020 8:09 am

To Georgina: Do you have preliminary results on the cost-effectiveness of your global approach? I mean at the consolidated cost level. Hervé Dombret, ParisPosted onJune 30, 2020 8:08 am

To Georgina: Do you have preliminary results on the cost-effectiveness of your global approach? I mean at the consolidated cost level. Hervé Dombret, ParisPosted onJune 30, 2020 8:07 am

To Georgina: Do you have preliminary results on the cost-effectiveness of your global approach? I mean at the consolidated cost level. Hervé Dombret, ParisPosted onJune 30, 2020 8:07 am

Georgina- Have you checked the utility of nano-string technique in B-ALL?Posted onJune 30, 2020 8:07 am

Have you checked the utility of nano-string technique in B-ALL?Posted onJune 30, 2020 8:07 am

To Georgina: Do you have preliminary results on the cost-effectiveness of your global approach? I mean at the consolidated cost level. Hervé Dombret, ParisPosted onJune 30, 2020 8:07 am

Have you checked the utility of nano-string technique in B-ALL?Posted onJune 30, 2020 8:06 am

To Georgina: Do you have preliminary results on the cost-effectiveness of your global approach? I mean at the consolidated cost level. Hervé Dombret, ParisPosted onJune 30, 2020 8:06 am

Question for Dr. Bullinger: How do you select gene markers for MRD analysis? How to avoid missing molecular relapse due to occurrence of new independent clones?Posted onJune 30, 2020 8:05 am

JM Ribera: You mention a deletion in IKZF3 gene at first relapse by MLPA and you do not mention TP53 del, however you found TP53 del in SNP array and no IKZF3 deletion, how do you explain these genetics differences between techniques?Posted onJune 30, 2020 7:42 am

Dear Sabina, Thanks for your lovely presentation! It's Wendy Stock. I just wanted to ask you whether you are now testing addition of ponatinib in the frontline setting for Ph-like ALL? Also, just to mention, in the US, we are now asking the question of whether inotuzumab in frontline setting (after induction) facilitates EFS for both Ph-like and non Ph-like ALL (trial number is A041501).Posted onJune 30, 2020 7:21 am

Could a whole transcriptome seq analysis approach reveal most of the genetic lesions in Ph-like cases?Posted onJune 30, 2020 7:16 am

Are there already multicenter trials which are based on this diagnosis?Posted onJune 30, 2020 7:16 am

Are the Ph-like expression profile changeable during treatment? Is it possible to lose this Ph-like features at the relapse?Posted onJune 30, 2020 7:13 am

Do we need more ICU beds in the future to be able to continue regular AML therapy?Posted onJune 30, 2020 6:53 am

Do we need more ICU beds in the future to be able to continue regular AML therapy?Posted onJune 30, 2020 6:53 am

Do we need more ICU beds in the future to be able to continue regular AML therapy?Posted onJune 30, 2020 6:53 am

Do we need more ICU beds in the future to be able to continue regular AML therapy?Posted onJune 30, 2020 6:53 am

We have screened AML/ALL and allo transplant patients pretreatment for 3 months. Found 1 positive pcr in 113 patients. Same is also true for pre-operative screenings in our hospital. How do you feel about the benefit (true positive vs false positive) and cost-effectiveness of covid pcr screening, especially now incidende is declining Europe? Is there any evidence of benefit at all? Posted onJune 30, 2020 6:50 am

Testing Posted onJune 30, 2020 6:34 am

Hello i have a question Posted onJune 30, 2020 5:23 am

testingPosted onJune 29, 2020 10:12 pm

HelloPosted onJune 28, 2020 6:19 pm

Hello this is a testPosted onJune 28, 2020 7:25 am

This is a testPosted onJune 26, 2020 9:22 am

Hello this is a question Posted onJune 26, 2020 8:55 am

This is a question Posted onJune 24, 2020 6:10 pm

I have a question to prof. SierraPosted onJune 24, 2020 5:48 pm

This is a quesitonPosted onJune 23, 2020 1:36 pm

Testing Posted onJune 23, 2020 1:22 pm

This is a test Posted onJune 23, 2020 1:17 pm

This is a test questionPosted onJune 22, 2020 8:10 pm